Needham Reiterates Buy Rating on Recursion Pharmaceuticals, Keeps $8 Target

Needham reiterated its Buy rating and $8.00 price target on Recursion Pharmaceuticals. The target implies 130.9% upside from the Oct. 16 close of $3.46.